Email Updates

Search form

You are here

AVAC in the News

  • First in-human data found that an implant for pre-exposure prophylaxis (PrEP) for HIV prevention was safe and long-acting, according to a small phase I trial presented here.

    July 23, 2019
    MedPage Today
  • In a major step forward for HIV vaccine research, the US research agency will partner with a pharmaceutical company on a large-scale, advanced-stage clinical study on an HIV vaccine. If the trial is successful, the vaccine may become the first ever to be approved for HIV prevention. But the rise of PrEP has created unexpected challenges to study enrollment.

    July 17, 2019
    The BodyPro
  • Johnson & Johnson is preparing to test an experimental HIV vaccine in the US and Europe in a move toward developing the first immunization against the deadly disease after decades of frustration. Some 3,800 men who have sex with men will receive a regimen of shots in a study that’s planned to be launched later this year, Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, said in an interview. The agency and the HIV Vaccine Trials Network of testing sites will collaborate with J&J’s Janssen unit on the effort.

    July 12, 2019
    Bloomberg
  • Reaching individuals at high risk of acquiring HIV infection continues to pose a challenge to uptake of HIV pre-exposure prophylaxis (PrEP). A new study looked at PrEP clinical trials in sub-Saharan Africa, examining recruitment strategies to reach women at high risk of contracting HIV.

    July 9, 2019
    Contagion Live
  • The debate on depo-provera increasing the risk of HIV acquisition started in 1996 when scientists discovered that monkeys injected with high concentration levels of depo-provera also known as DMPA by scientists had their biological make-up weakening, thereby allowing easy penetration of SIV, an equivalent of HIV in humans, into their system.

    June 25, 2019
    The Herald
  • The HIV Research for Prevention (HIVR4P) conference is dedicated to advancing HIV prevention research, responding to a growing consensus that effective and durable prevention will require a combination of approaches as well as unprecedented collaboration among scientists, practitioners, and community workers from different fields and geographic areas. The conference theme in 2018, “From Research to Impact,” acknowledged an increasing focus on translation of promising research findings into practical, accessible, and affordable HIV prevention options for those who need them worldwide.

    May 29, 2019
    General
    AIDS Research and Human Retroviruses
  • The implications of the anti-vaccination movement are enormous. Just as vaccines against some of the greatest global killers finally come within reach, fear and misinformation could diminish vital commitments to continued vaccine research, and important investments in vaccine education and delivery. Effective vaccines might not get developed, manufactured, distributed or used due to misguided, anti-vaccine sentiment — potentially putting millions of people at risk for entirely preventable deaths and diseases.

    May 17, 2019
    Science Speaks
  • Gilead Sciences, maker of Truvada, the only drug approved to prevent infection with HIV, will donate enough of the drug to supply 200,000 patients annually for up to 11 years, federal health officials announced on Thursday.

    May 9, 2019
    New York Times
  • The unnamed “London patient” — the second person apparently cured of HIV — earned all the headlines. But other research released this week at the Conference on Retroviruses and Opportunistic Infections showed that scientists are making slow but steady progress on the tactics and medicines needed to fight the epidemic, especially in Africa.

    March 8, 2019
    New York Times
  • Monthly shots of HIV drugs worked as well as daily pills to control the virus that causes AIDS in two large international tests, researchers reported Thursday.

    March 7, 2019
    Associated Press

Pages